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Since streptokinase and urokinase became available for
clinical use, numerous attempts have been made to im-
prove these useful thrombolytic agents. To decrease its
antigenicity, streptokinase has been fragmented or cou-
pled to human plasminogen or polethylene glycols. With
a plasmin B chain-streptokinase complex a more potent
agent was obtained. To prolong their half-lite, strepto-
kinase and urokinase were immobilized with water-
soluble carriers. Coupling urokinase with fibrin-specific
Historical background. The first attempts to perform
enzymatic thrombolysis date back to the 1950s when it was
shown that trypsin and chymotrypsin produced a significant
increase in circulating proteolytic activity in animal models
but resulted in poor dissolution of arterial thrombi. Brave
attempts with trypsin in patients were a moderate success
in terms of proved thrombolysis (I); the hazard of induced
in vivo coagulation and the frequent production of local
thrombophlebitis resulted in abandonment of this agent. Two
American groups (2,3) and a European group (4) started
their pioneering work with streptokinase, at that time a rather
pyrogenic substance. A few years later some animal studies
were reported on thrombin E, the acetylated form of throm -
bin that retains esterolytic activity but loses its clotting power;
however, these initial animal experiments with thrombin E
were not pursued (5). There were numerous clinical trials,
published between 1960 and 1970, of two commercial prep-
arations, Actase (Ortho) and Thrombolysin (Merck Sharp
& Dohme), which were mixtures of human plasmin and
streptokinase; it is most likely that the clinical result obtained
with these two agents was primarily attributable to their
streptokinase content (6).
In the last two decades thrombolytic therapy with either
streptokinase or urokinase has emerged as a practical and
useful method of management of certain forms of throm-
boembolic disease (7,8). However, streptokinase and uro-
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antihodies increases its thrombolytic efficacy, at least in
vitro. The only thrombolytic agents with a relative fibrin
specificity available for clinical purposes are tissue-type
plasminogen activator and single chain urokinase-type
plasminogen activator. Mutants and hybrids of these
molecules are being constructed and may further im-
prove their fibrin specificity and therapeutic potential.
(J Am Coli Cardiol 1987;10:4B-1OB)
kinase possess little specific affinity for fibrin and therefore
activate circulating and fibrin-bound plasminogen relatively
indiscriminately. Consequently, plasmin formed in circu-
lating blood is initially neutralized very rapidly by alphaT
antiplasmin and is lost for thrombolysis. Once the inhibitor
capacity becomes (nearly) exhausted. residual plasmin de-
grades several plasma proteins (fibrinogen, factor V, factor
VIII, and so on), which may cause serious bleeding. Several
attempts have been made to increase the thrombus specificity
of streptokinase and urokinase by methods based on prior
administration to the patient of lysine-plasminogen, which
has a higher affinity for fibrin than does glutamic acid-
plasminogen (9), or based on the removal of alphaT
antiplasmin by prior plasmin infusions (10) or administra-
tion of dextran (II) or orthothymotic acid (12). None of
these approaches have gained general acceptance.
Streptokinase Preparations
Streptokinase fragments. Streptokinase itself has nei-
ther protease nor esterase activity; when streptokinase and
human plasminogen are mixed, a I: I stoichiometric com-
plex is formed and an active serine hydrolytic center is
exposed; this complex activates plasminogen (13,14). The
process of activation involves the release of peptide material
of approximately Mr 8,000 from the aminoterminal end of
native streptokinase (15). This streptokinase fragment pos-
sesses approximately 50 to 60% cross-reactivity with human
antistreptokinase antibodies; smaller molecular weight
streptokinase fragments appear to bind still less poorly to
immunoglobulins against native streptokinase but also ac-
tivate weakly human plasminogen (16,17). Although the
0735- 1097/87/$3.50





streptokinase molecule present in the I : I streptokinase-
plasminogen complex contains fewer accessible antigenic
determinants than does the intact molecule. the complex is
still antigenic and immunogenic in humans (18).
Streptokinase coupled to polyethylene glycols. Strep-
tokinase. having a bacterial origin. is a foreign protein in
humans and thus has antigenic and immunogenic properties.
Attempts have been made to chemically modify strcptoki-
nase to produce derivatives that are nonanti genic . The po-
tential advantages are that the initial loading dose of mod-
ified streptokinase would not first have to overcome the
existing antibody titer. could still be utilized in patients with
high antibody titers and could allow a longer treatment du-
ration.
The reactivity of streptokinase with antibody can be con-
siderably decreased by conjugating the protein to poly-
ethylene glycol (lvI , 5.000 ), a nonantigenic polymer: how-
ever. this polyethylene glycol streptokinase derivative loses
67 to 93% of its original plasminogen-activating property.
When polyethylene glycols of lower molecular weight (2.000
or 4.000) are activated with carbonyldiimidaw le and co-
valently coupled to streptokinase. a good plasminogen ac-
tivator function in vitro is maintained and the complex j,
protected from proteolytic degradation but has lost 90 to
95% of the capacity to bind to immunoglobulins (19,20) .
Plasminogen activator complexes formed with strepto-
kinase coupled to polyethylene glycol of M, l.OOO to 4 .000
are cleared from the circulation of mice at a slower rate than
is the complex formed with unmodified streptokinase. It is
therefore likely that the reaction of alpha--macroglobulin
with polyethylene glycol-streptokinase activator complex
occurs less readily. It is indeed known that the a l pha~ ­
macroglobulin-plasmin complex is cleared from the circu-
lation by way of specific alph ayrnacroglobulin protease re-
ceptors in the liver (20). Streptokinase released from the
complex also clears in the liver and may exist in a degraded
form that clears more rapidly than native streptokinase ( 15) .
Cleavage of fibrin apparently is favored by binding of poly-
ethylene glycol-streptokinase-plasmin(ogen) complex. This
reaction may occur because the complex clears so much
more slowlywhen modified by polyethylene glycol. It is
interesting to note that plasmin complex with polyethylene
glycol-modified streptokinase also displays an increasedcir-
culatory half-life in mice (21).
Immobilized fibrinolytic enzymes. The production of
immobilized enzymes is a novel development in bioengi-
neering. Numerous methods have been described of enzyme
stabilization by means of electrostatic or covalent binding
on water-soluble or water-insoluble polymeric carriers such
as agarosc, nylon. collagen and heparin (22).
Thrombolytic enzymes can be bound with water-soluble
carriers to prolong their survival in the circulation (D) .
Dextrans of different molecular weight activated by oxi-
dative incorporation of aldehyde groups have been used to
immobilize plasmin. In optimal conditions. the binding de-
gree was as high as 95(/(, (190 mg protein/g of carrier) with
gS% preservation of the esterolytic activity. The specific
fibrinolytic activity was about 22 units/mg of the preparation
(24).
Streptokinase has beell immobilized 0 11 soluble activated
dextran (Mr 35 .000 to 50 .000); it has a prolonged half-life
(up to gOhours) and can therefore be administered in a bolus
(25). The Russian commercial preparation Streptodekaza
has been used in patients with acute myocardial infarction
and deep vein thrombosis (26.27). According to the reports
published in Russian medical journals only. systemic acti-
vation of the fibrinol ytic system is minimal and the molecule
appears not to be immunogenic.
A variety of procedures were used to immobilize urok i-
nase on activated dextran (28.29) or on soluble acrylamidc-
acrylic acid copolymers (30 .3 1). Up to 180 mg urokinase
can be bound per gram of the synthetic polymer: the im-
mobilization yield is 90% with almost unchanged enzyme
activity (3 2) .
Heparin has been used as a carrier [or plasmin and
urokinase. Heparin is rich in reactive carboxylic groups that
can interact with amino groups of proteins on preliminary
activation with water-soluble carbodiimide (33). Prepara-
tions were obtained with a binding degree of urokinase of
947<· and with reasonable preservation of enzyme activity
(80 to 85o/c). The anticoagulant activity of heparin appears
10 remain unchanged. The use of preparations having both
thrombolytic and anticoagulant properties is attractive. par-
ticularly if these agents are fibrin specifi c. Because vascular
spasm is a frequent companion of thrombosis and arterial
embolism. it may be desirable to have molecules dispensing
thrombolytic. anticoagulant and vasodilating properties. So-
dium nitroprusside, a vasodilatorwitha low molecular weight.
attaches to urokinase through its sulfhydryl groups. It is still
possible to conjugate heparin-bound urokinase to nitro-
prusside, resulting in a preparation with a triple action close
to the corresponding activity of each individual component
(34). Whether drugs with such multiple profile properties
in vitro would fulfill their theoretical promises in humans
is still to he demonstrated .
Plasmin B-chain-strcptokinase complex. A complex
orthe plasmin B-chain with streptokinase has been prepared
and is a potent activator of plasminogen (35-39). However.
because this complex lacks the lysine-binding sites of plas-
minogen it can be anticipated to be a less fibrin-specifi c
thrombolytic agent. The plasmin B-ehain- streptokinase
complex was shown to be four to eight times more potent
as a thrombolytic agent in a jugular vein thrombosis model
in the dog than was the plasminogen-streptokinase complex
(40). It is possible that the streptokinase moiety is in a
slightly different configuration in the plasmin B-
chain- streptokinase complex. which may account for its
lesser binding to streptokinase antibodies. Plasmin B-chain
appears to have a greater affinity for plasminogen trapped
in the thrombus (40) .
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Fibrin-Specific Thrombolysis
The three most recent approaches toward fibrin-specific
thrombolysis have been the development of stable acyl de-
rivatives of an equimolar streptokinase-plasminogen com-
plex and the isolation of both human tissue-type plasmin-
ogen activator and a single chain form of urokinase.
Acylated equimolar streptokinase-plasminogen com-
plex. Equimolar complexes of streptokinase and human
lysine-plasminogen have been prepared in which the cata-
lyticcenterof the plasminogen moleculeis covalentlybound
to an acyl group. Because the fibrin-binding site of plas-
minogcn is functionally separate from its enzymatic site,
the complex can still bind to fibrin through the unmodified
kringle domains of plasminogen (41,42). The complex is
thus targeted to the vascular thrombus. The acyl group is
hydrolyzed off whenthe freeze-dried compoundisdissolved
in the blood at a rate depending on the acyl group used.
With a p-anisoyl derivative (Beecham BRL 26921, Im-
munase) the in vivo deacylation half-time is about 20 min-
utes.
In a thromboticmodel in animals, acylatedstreptokinase-
plasminogen was significantly more thrombolytic than was
the enzymatically unblocked streptokinase-plasminogen
complex, both given as a bolus (42,43). In human volun-
teers, 5 mg of the BRL 26921 compound had little effect
on the systemic fibrinolytic system; this dose is on a molar
basis equivalent to 178,000 IV streptokinase, which produces
a significant decrease of fibrinogen and plasminogen (44).
Above 5 mg, progressive reductions were observed in plasma
levels of fibrinogen, plasminogen and alpha--antiplasmin
(45-47). The recommended dose in acute myocardial in-
farction is 30 mg, given in a bolus. With this dose a high
reperfusion rate of 85% is achieved, which is superior to
that reported for up to 1.5 million units of streptokinase
(48). However, the adverse event profile of 30 mg BRL
26921, also in terms of its systemic activation of the fi-
brinolytic system, appears to be quantitatively similar to
that described for streptokinase (49).
Tissue-type plasminogen activator. Tissue-type plas-
minogen activator (t-PA) has been isolated and purified from
human uterine tissue (50) and from a human melanoma cell
line (51). The gene for human t-PA has been cloned and
recombinant tissue-type plasminogen activator (rt-PA) ex-
pressed (52). Tissue-type plasminogen activator is a gly-
cosylated serine protease secreted by the vascularendothe-
lium as a one chain molecule (70 kdalton) . Cleavageof the
arginine 275-isoleucine 276 peptide bond by plasmin or
trypsin converts the molecule to a two chain form (51 -53).
The light chain (32 kdaIton) contains the enzymatic center
in its carboxy-terminal part with the histidine, aspartic acid
and serine residues common to all trypsin-like serine pro-
teases (52,54,55). The heavy chain (36 kdaIton) harbors
several domains found in other proteins. Starting from the
amino terminal end there is the signal sequence, a prose-
quence similar to the one found in human serum albumin
(56), a "finger domain" similar to type I "fingers" on
fibronectin (57-59), an "epidermal growth-factordomain"
homologous to mouse and human epidermal growth factor
(59) and two "kringle domains" that share a high degree
of homology with the five kringlesof plasminogenand with
the single kringle in urokinase.
A unique property of tissue-type plasminogen activator
is its very high affinity for fibrin (60) . The structures in-
volved in the binding of tissue-type plasminogen activator
to fibrin appear to be the lysine-binding site present in the
second kringle of t-PA and, to a minor extent, its finger
domain (61,62). On the fibrin surface, single chain t-PA is
quickly converted to a two chain form during fibrinolysis
but there is no evidence that this conversion plays a role in
the regulation of fibrinolysis (63).
Kinetically, in the absence of fibrin, t-PA has a weak
affinity for plasminogen. For an enzyme to react with its
substrate, efficient generation of the active enzyme is de-
pendent on its affinity and efficiency. The tightness of the
interaction between the enzyme and its substrate is the af-
finity (low Michaelis constant [Kill])' Once the interaction
has occurred, the efficiency with which the reaction pro-
ceeds is termed turnover (high k"ol)' Tissue-type plasmin-
ogen activator, in the absence of fibrin, reacts only very
slowly with plasminogen because of a high K", (low affin-
ity). Therefore, very little plasminogen activation will occur
in the circulation (fluidphaseof blood) at physiologic levels
of t-PA. However, in the presence of fibrin (thrombus), t-
PA has a very high affinity (low Kill) for plasminogen. When
t-PA and plasminogen are both bound to the fibrin surface,
the conformation of the two molecules is altered greatly,
facilitating the plasminogen activation (64,65). Kinetic data
support a mechanism in which t-PA and plasminogen align
on the fibrin matrix to form a cyclic ternary complex (65),
One eWI thus conclude that the increased affinity of T-
PA for plasminogen is a result ()f its alignment on the fibrin
surface . Fibrin essentially increases the local plasminogen
concentrations, creating an additional interaction between
t-PA and its substrate througha cyclic fibrin bridge. Plasmin
is thus predominantly generatedon the fibrin surface. which
prevents proteolytic activity of plasmin in the circulation .
Moreover, because fibrin-bound plasmin has both its lysine-
binding sites and active site occupied, it is only slowly
inactivated by alpha--antiplasmin. Poly-L-lysine and certain
mixed polymers of L-Iysine and other amino acids modify
the activityof one- and two-chain t-PA towardits substrates.
In particular, the rate of plasminogen activation in the pres-
ence of optimal poly-L-lysine concentrations is increased
by approximately 100-fold (66).
Single and double chain urokinase-type plasminogen
activator. A plasminogen activator has been discovered
and isolatedfrom human urine, conditionedmedia of human
embryonic kidney cell cultures (67) and certain tumor cells
(68). Wrongly considered to be a kinase, the name urokinase
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was adopted; because the enzyme is also present in the blood
(2 to 5 Ilg/liter). it is now more appropriately designated
as urokinase-type plasminogen activator (u-PA) (69).
Several investigators have shown that a precursor form
of urokinase can be isolated from human embryonic kidney
cells and also from urine. This precursor of urokinase can
also be obtained by recombinantdeoxyribonucleic acid (DNA)
methodology. It is a single chain glycoprotein containing
4 11 amino acids with 24 cysteine residues (single chain
urokinase-type plasminogen activator. scu-PA or pro-
urokinase) (70-72).
Kinetic studies have shown that. in a purified system.
scu-PA is a direct activator of plasminogen characterized
by a high affinity (73.74) but that it has a low reactivity
toward low molecularweight synthetic substrates or reactive
site titrants (74-76). However. in a plasma system. scu-PA
does not signifi cantly activate plasminogen. apparently be-
cause a component in plasma competes with plasminogen
for binding of scu-PA (73). Efficient fib rinolysis without
fibrinogenolysis is observed on addition to plasma of fibrin
or fi brin fragments (77.78). This apparent fibrin specifici ty
of scu-PA has been explained in two ways. According to
one school of thought. activation of plasminogen by scu-
PA in plasma or circulating blood is prevented by a com-
petitive inhibitor (74); the presence of fibrin would revert
this inhibition. The amino terminal and kringle-containing
portions of scu-PA are not involved in this process; which
specific structure is responsible for this unique action re-
mains to be defined. An alternative view is that scu-PA
binds directly to fibrin and activates the fibrin-bound plas-
minogen but is inactive toward circulating plasminogen. In
this concept. scu-PA would display at the fibrin surface some
intrinsic plasminogen activator activity. which would trigger
the reciprocal activation of fibrin-bound scu-PA and plas-
minogen. the latter being in its lysine-plasminogen-like
configuration (79).
Newer Fibrin-Specific Thrombolytic Agents
More recently. attempts have been made to obtain other
fibrin-specific thrombolytic agents by chemical modification
of known fibrinolytic substances. A further aim is to increase
the half-life of these novel agents in the circulation. None
of the novel agents have been studied so far in patients. at
least not in a systematic manner.
Conjugates of plasmin heavy chain with urokinase.
Plasmin consists of a light and a heavy chain linked by
disulfidebonds. The light chain contains the catalytic center
whereas the heavy chain is composed of fi ve homologous
triple loop structures or kringle regions (80). The lysine-
binding sites located in kringles I to 3 and kringle 4 are
responsible for the binding of plasminogen to fibrin (81).
The heavy chain of plasmin has been coupled to low mo-
lecular weight urokinase by the maleirnide-sulfhydryl re-
action (82). The resulting conjugate was shown not to main-
tain a high fibrinol ytic activity 'and to have acquired a high
affi nity for fibrin in vitro. resulting in about 10 times higher
thrombolytic activity than that of high molecular weight
urokinase in vivo in a pulmonary embolism model in rabbits.
The half-life of the conjugate was about three times longer
than that of high molecular weight urokinase. but this was
also the case if human serum albumin was conjugated with
urokinase. The higher thrombolytic activity of the plasmin
heavy chain conjugate with urokinase can therefore be as-
cribed to its increased fibrin binding.
Urokinase coupled with fibrin-specific antibody. Among
the various methods of drug targeting. the use of specific
antibodies as vector molecules is highly attractive (83).
However. direct binding to an antibody decreases its specific
activity. To circumvent this problem and increase the amount
of drug bound to immunoglobulins. formation of a poly-
meric bridge by way of activated dextran macromolecules
was proposed (84). Using periodate-activated dextran as a
polymeric bridge. plasmin has been bound with polyclonal
antibodies against fi brinogen (85).
Because there is 98% identity in the primary structures
of fi brinogen and fibrin. it is difficult to develop antibodies
that differentiate between these two molecules. In ingenious
experiments. Hui et al. (86) developed antibodies against a
part of the beta-chain of fibrinogen that reveals a new amino
terminal after thrombin has broken off a small peptide (pep-
tide B). A peptide corresponding to the seven amino terminal
residues of the beta-chain of human fi brin (glycine-histidine-
arginine-proline-Ieucine-aspartic acid-lysine-cysteine) was
synthesized. This epitope was linked to a carrier protein
that served as an immunogen in mice. and a monoclonal
antibody specifi c for fibrin was obtained by somatic cell
fusion. Reduced urokinase was then coupled to the mono-
clonal antibody by means of its intrinsic sulfhydryl groups.
with N-succinimidyl-3-(2-pyridildithio)propionate as a cross-
linking agent. In vitro experiments have shown that the
antibody used is sufficiently fibrin specific so that physio-
logic concentrations of fi brinogen do not interfere with the
enhanced fi brinolysis (87). Fibrinolytic effectiveness was
not increased by the coupling of urokinase to a monoclonal
antibody of irrelevant specificity and was shown to be de-
creased by a peptide representing the epitope recognized by
the fibrin-specific antibody.
By virtue of enhanced local concentration. this fibrin-
directed urokinase was shown to increase IDO-fold the ef-
ficiency of fi brinolysis in vitro (88). If these effects can be
demonstrated in vivo. the lowered dose of urokinase re-
quired for effective thrombolysis will result in only minimal
fibrinogenolysis. Also conjugates of fibrin-directed anti-
bodies. either with rt-PA or with scu-PA. may result in a
still higher affi nity for fi brin of the latter agents (89).
Mutants of tissue plasminogen activator. Because t-
PA is a mosaic protein with different domains. it would be
most instructive to know which parts of the molecule are
responsible for the different molecular interactions of the
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enzyme. Development of new techniques makes it possible
to create mutants of t-PA with specifi c deletions or amino
acid substitutions by in vitro mutagenesis. The production
of these mutant proteins is made feasible because of the
availability of the genetic blue print of the DNA coding for
the complete t-PA protein and of an expression system-pro-
ducing the recombinant protein (52.90).
By expressing the coding only for the light chain portion
of the t-PA molecule, MacDonald et al. (91) were able to
demonstrate that this part of the molecule has plasminogen-
activator activity and retains the plasminogen specificity of
the native t-PA molecule but does not exhibit the fibrin-
stimulating activity of the latter. In a study (92) using mono-
clonal antibodies against an epitope covering the active en-
zymatic site of t-PA, the same conclusion was reached.
Deletion-mutant proteins containing differentdomains of
the heavy chain together with the light chain of rt-PA have
been produced (90). The finger domain and, more impor-
tantly, the kringle 2 appear each to have an autonomous
function in the binding to fibrin and in mediating the stim-
ulation of the plasminogen activator activity of rt-PA by
fibrin. Notwithstanding the fact that the two kringles are
highly homologous, subtle differences must prevent kringJc
I from having the fibrin-binding property. Confirming these
elegant experiments is the finding that monoclonal antibod-
ies. which were found to inhibit in part llbrin binding of rt-
PA, were especially bound to kringle 2 (93,94). A mutant
of the molecule in which the first krinzle is replaced bv ae- J
copy of the second kringle might therefore have improved
fibrin-b inding properties. The fact that a " fi ngerless" tissue-
type urokinase plasminogen activator protein retains high
affi nity for fibrin (61) further supports the conclusion that,
in addition to the lingerdomain, another part of the molecule
is involved in fibrin binding. A lysine-binding site is in-
volved in the interactionof the kringle-2domain with fibrin,
but not in the interaction of the finger domain with fibrin
(95).
Mutants of single chain urokinase-type plasminogen
activator. Single chain urokinase-type plasminogen acti-
vator differs markedly from urokinase with respect to fibrin -
specific thrombolytic properties. Site-specific mutagenesis
of scu-PA around the cleavage site therefore might yield a
more stable molecule. A low molecular weight form of scu-
PA activator with leucine 144in the amino terminal position
was found to be functionally indistinguishable from intact
scu-PA. Low molecular weight single chain urokinase-type
plasminogen activator may therefore be preferable over in-
tact scu-PA for the large scale production of this molecule
by recombinant DNAtechnology. Nelles et al. (unpublished
observations) recently constructed and characterized both
lysine 158 mutants of scu-PA and constructed a low mo-
lecular weight scu-PA by recombinant DNA technology;
investigations of the biologic and thrombolytic properties
of these molecules are in progress.
Conclusions
Since the discovery of natural fibrin-specificthrombolytic
agents. remarkable progress has been made on deepening
the knowledge of the fibrinolytic process. The recognition
that molecular domains of t-PA and scu-FA are homologous
to regions in other plasma proteins has considerablv im-
proved the understanding of the structure-function relation
of these domains. These investigations became feasible be-
cause well characterized molecular fragments of tissue-type
plasminogen activator and of single chain urokinase-type
plasminogen activator could be isolated and because mono-
clonal antibodies could be obtained against these various
domains. As the full length eDNA clones of t-PA and scu-
PA have been isolated and expressed. structural manipu-
lation allows the design and production of mutant proteins
with specific deletions, additions or substitutions of non-
protease domains. This fascinating technology opens the
way to construct new molecules with potentiated biologic
effects. Chimeric molecules combining fragments of t-PA
and scu-PA have already been constructed. One of the first
reports on this endeavor of molecular biology is presented
in the following article (96).
References
I. Innertield I. A~gri st A. Schwarz A. Parenteral administration of tryp-
sm. clinical effect In 53H patients. JAMA 1953:152:597-605.
2. Johnson AJ. McCarthy WR. The lysis of artificially induced intra-
vascular clots in man by intravenous infusions of streptokinase . J C1in
Invest I959:3H: 1627--43.
3. Sherry S. l.indemeyer RI. Fletcher AP, Alkjacrsig N. Studies on
enhanced fibrinolytic activity in man. J Cl in Invest 1959:3&:810 - 22 .
4 . Gross R. Hartl W. Kloss G . Rahn B. Tnrombol yse durch Infusionen
hochgereinigter Streptokinase. Erfuhrungen uno Untersuchungen an
den ersten 50 Krankcn. Dtsch Med Wochenschr 1960:85:1129-41.
5. Seegers WH, Landaburu RH. Johnson JI' . Thrombin E as a fibrinolytic
enzyme. SCience 1Y60: 131 :726.
6 . Sawyer WD, Alkjaersig N, Fletcher AP. Sherry S. Thrombolyt ic
therapy. Arch Intern Med 1961 :I 07:274-8'J.
7. Brogden RN. Speight TM. Avery CiS. Streptokinase: a review of its
clinical pharmacology, mechanism of action and therapeutic uses.
Drugs 1973;5:357-445.
8 . Sherry S. Therapeutic thromb olysis: past. present and future. In: Pa-
oletti R. Sherry S. eds. Thromb osis and Urokinase. London: Academic
Press. 1977:1- 9 .
9. Kakkar VV, Sagar S. Lewis M. Treatment nf deep vein thrombosis
with intermittent streptokinuse and plasminogen infusion. Lancet 1975:2:
674-6 .
10. Marbe t GA , Eichlisberger R. Duckett F. et al. Side effects of throm-
bolytic treatment with porcin e plasmin atul luw dose streptokinase.
Thromb Haernost 1982:48:196-2UO.
II . Carlin G. Saldeen T. On the interaction between dextran and the
primary fibrinolysis inhibitor (f,-anti pla~m i n . Thromh Res 19XO; 19:
103- 10.
12. Prandini :VIH. Wiman B. Samarna M. Collen D. Effecls of the svn-
thetic fibrinolytic agents ort ho-thymouc acid and S-1623 on the re-
action between human plasmin and antiplasmin. Thromb Res 1978 ; 13:
165-73.
13. McClintock DK_ Bell PH. The mechanism of activation of human
JACC Vol. 10. No.5
November 19X7:4B-IOB
VERSTRAETE
IDEAL THROMI10 l. YTIC AGENTS
9B
plasminogen by streptokinase. Biochem Biophys Res Commun 11)71:43:
694-702 .
14. Reddy KNN. Markus G. Mechanism of activation of human plas-
minogen by SK. J Bioi Chem 1972:247: 16H3- 91.
15. Brockway W1. Casrellino FJ. A characterization of native streptoki-
nase and altered streptokinase isolated from a human plasminogen
activator complex. Biochemistry I974: 1 3 : 206.~ -7(J .
16. Barlow GH. Levine E. Finley R. Immunological and biochemica l
comparison of streptokinase and the streptokinase plasminogen co m-
plcx. Res Commun Chern Pathol Pharmacol 11)75:10:465- 71.
17. Barlow GH. Finley R. Castellino FJ. Immunological co m par iso n of
native streptokinase with streptokinase fragments. Thromh Res 1976:H:
237-42 .
IX. Verstraete M. Vermylen J. Holleman W. Barlow GH. Biological
effects of the administration of an equimolar streptokinase-plasmin -
ogen complex in man. Thrornb Res 1977: II :227- 36.
19. Koide A. Suzuki S. Kobayashi S. Preparation of polyethylene glycol-
modified streptokinase with disappearance of binding ability towards
anti-serum and retention of activity. FEBS Lett 19X2:143:73-6.
20. Rajagopalan S. Gunias SL. Pizzo SV. A nonantigcnic covalent strep-
tokinase-polyethylene glycol complex with plasminogen activator
function. J Clin Invest 19X5:75:413- I).
21. Rajagopalan S. Gonias SL. Pizzo SV. A pharmacologically modified
streptokinase-polyethylene glyco l complex (abstn . J Cell Biochem
19X7: IX7(suppl):181.
22. Torchilin VI' . Immobilized enzymes and the usc of immobilization.
Principles for drug targeting. In: Goldberg ED. ed. Targeted Drugs.
New York: John Wiley and Sons. IYX3:127- 52.
23. Marshall J1. Humphreys JD. Abramson SZ. Attachment of carbo-
hydrate to enzymes increases their circulation lifetimes. FEBS Lett
1972:X3:24Y- 52.
24. Chazov EI. Mazaev AV. Torchilin VI' . ct al. Experimental study of
biosoluble drugs. Thrombus lysis with biosolublc immobilized tibri-
nolysis in experiment. Thrornb Res 197X:12:X09-1 6.
25. Torchilin VI' . Voronkov YuI. Mazacv AV. Use of immobilized strep-
tokinase (Streptodckaza) for thrombosis treatment. Ter Arkh 19X2:54:
21-6 .
26 . Chazov EI. Smirnov VN. Suvorova LA. et al. Influence of a new
thrombolytic preparation "Streptodekaza" on the fibrinolysis system.
Kardiologiia (Russ) 198I:21: 18-21.
27. Torchilin VI' . Trubetskov VS. Stabilization of subunit enzymes by
intramolecular crosslinking with bifunctional reagents. Ann NY Acad
Sci 1984;434:27-30.
28. 19a Y. Kitamura M. Chikamori K. Okamura Y. Urokinase derivatives
and its production method. Japanese patent no 11 3488. 1979.
2Y. Maksimenko AV. Torchilin VI'. Smirnov VN. Chazov EI. Heat-
resistant water-soluble urokinase derivative. US patent no 4349630.
IY82.
30. Maksimenko AV. Torchilin VI' . Smirnov VN. Chazov El. Stabilized
derivatives of urokinase possessing thrombolytic activity and the method
of preparation thereof. Invention of the USSR no 93Hh17. 19K2.
31. Holeman WHo Lee SG. Hung PI'. Modified urokinase extend activity
and methods of making. US patent no 4326033. 1982.
32. Papisov MI. Maksimenko AV. Torchilin VI'. The optimization of
reaction conditions during enzyme immobilization on soluble car-
boxyl-containing carriers. Enzyme Microbiol Technol 1985:7:11- 6.
33. Torchilin VI'. lIyna EV. Streltsova LA. Smirnov VN. Chawv EI.
Enzyme immobilization of heparin. J Bioi Mat Res 1978:12:585- 90.
34. Maksimcnko AV. Tnrchilin VI'. Water-soluble urokinase derivatives
of combined action. Thromb Res I9X5 : .~ 8 :2 77-88 .
35. Summaria L. Robbins KC. Isolation ofa human plasmin-derived func-
tionally active. light (B)chain capahle of fonning with streptokinase
an cquimolar light (B) chain-streptokinase complex with plasminogen
activator activity. J BioI Chem 197f>:25I :5X10- 3.
36. Summaria L. Borci-ha lG. Arzadun L. Robbins Kt,' . The dissolution
of human ero-s-l inked librin clots by the cquimolar human plasmin-
derived light (Hlchain-strcptokinuse complex. The acceleration of d ot
lysis by pretreatment of fibrin d ots with the light tB xhu in . Thromb
Res 11J/ 7: I U 77-·8l} .
.' 7. Wnhl RC. Summaria L. Ami don L. Robbins KC. Steady state kinetic-
of activation of human and bovine plasminogen by streptokina-c and
its cquimolar cumplexc-, with various activated torm-, of human plas-
minogen. .I Bio! Chern 1978:2:>4:1402- 7.
.' K. Robhin-, KC. Wohl RC. Summaria L. Activutiun oj human plasmin-
ogen in hnth purified ~ys tems and plasma by strcptukinase and uro-
kinase act ivato r -pcc ic- . In: Davidson JF. Cepelak V. Sumama M\1.
Desnoye rs Pt.'. cds . I'mgress in Chemical Fihrin ulysis and Throm-
bnlysis . ""I IV. l.dinburgh: Churchi l l Livingstone. 1979:3311-8.
3Y. Wohl RC. Sunnuaria L. Ruhhins KC. Kinetics of activation of humun
plasminogen by different species at pH 7..\ and 3T'C .I Bi,,1 Chern
1980:255:21105- 113
40. Summari.r L. S;lIlde~:.Jra J. Yang G. Vaghcr .II'. Caprin: JA. In vitrn
comparison "" fibrinolytic al·tlvity of plasminogen activators using a
lhromboclastoeraphic method: in vivo cvuluatiun oj the !:l-chaln·strep·
tokinase complex III the dng model using prctucrcd doses . Th rorub
Hacmoxt I% h:5fl:71-LJ .
41. Smith RAC;. Dupe RJ. English I'D. Green J. H bri noly- }, with ucyl-
enzyme»: a new approach h I thrnmbolvtic therapy. Nature 1')8 1:290:
50S-X.
42 . Smith R:\ G. Dupe R.I. English I'D. Green J. Acyl-cnzymc-, as throm-
bolyti r "gem, in rabbit model of venous thro mbu- is . Th rornh Hacmoxt
1982A7:2f> tJ- 74.
43. Dupe RJ. English PD. Smith RA(j . Green J. Acyl-enzymes arul thrum-
bolytic agem ~ in dog m.ulcl-, (11' VCI1(l U, thrmuhosi» and pulmonary
cmhulivm. Thrumh Hacmo-i I'ilS4:5 1:24X- 53
44. Prowse CV. Hornvcy V, Rucklcy C\' . Bolton I'E . A comparison Ill'
ucykued -rreptnkina-c-plasnnnoecn complex ami -arepto kina-c in heal1hy
volunteers . Thrumb Hacmn-t 1982:47:132-45.
45. Murder V1. Frunci-, CWo Norry EC. Dose-ranging study of acylutcd
strcptokina-c-plasminogcn complex (BRL-2h'>211 (ahxtr). Thromb
Hacmu-t ILJI(3:51U21.
46. Marder V1. Rothbanl RL. Htzp.rt rirk PC; . Francis CW Rapid lysis
of coronary artery thrombi with unisoylated pla"lllllogen : streptoki-
nase activator complex. Ann Intern vled 19l56:104:J04-IO.
47 , Earnshaw J1. Wcsthv .Ie. Makin GS. Hopkinsun BR. The systemic
Iibrinolyuc citurt of I3RL 2h921 during the treatment of acute pe-
ripheral arterial occlusion s. Thromb Haemust 1986:55:259-62 .
4lS . Spann JF. Sherry S. Coronary throtuholysi-, for evolving myocardial
infurctiun. Drugs ll} lS4 :2X :4f1."- 83.
4l} . Been Iv!. de Bono DP. Muir AL. ct ul. Clinical cnc ct- and kinetic
properties of imravcnous APSAC-;lI1isoyb ted plasminogen-strepto-
kinase uctivaror complex i BRL 2(92 1) in acute myocardi al infarction .
Int J Cardi,,1 19X6:11:53- 6 1.
50. Rijkcn DC. Wljn~;rard, G. I."al-de Jong M. Wclbcrgen 1. Purification
and partial characterization " I' plasminogen activator from human uter-
ine tissur. Hiochun Biophy-, Acta 1974:580:140- 53.
51. Rijkcn DC, Collen D. Purification and churactcrizuuun of the pb s-
minogen activator secreted oy human melanoma ccll-. in culture. J
!:lilll Chern ILJXI: 156:7035- 41.
52. Pennica D. Holme- WE. Knhr WJ. ct al . Cloning and cxprc- -ion nf
buman tissue-Iype plasminogen activator r DNA in E. coli. " ature
19K'l:JOI:214-21.
53. Wall"n P. Poh! G. Bcrg'dorf N. el al. Purilication and characlerizali'lil
of a lllelanl1ma cell plasminogen aeti\·alor. Em .l Bi"chem 1983:132:
r,x1- (1.
54. Dodd I. Fears R. RobinSllll JH. Isolation and preliminary charackr-
ization of aCllve f:!-challl of recombinant tissue-type pla,minogen aL:-
tivator. Thwmh H'lelllo,t I'JX6:55:94-7
55. Rijken DC. (,roenevcld E. Isolation and functional ch;rracterilation
lOB VERSTRAETE
IDEALTHROMBOLYTIC AGENTS
lACC Vol. 10. No.5
November 19X7:4B-IOB
of the heavy and light chain of human tissue-type plasminogen acti-
vator. J Bioi Chem I9~6;261:3098-1 02.
56. Lawn RM, Adelman 1, Bock SE, et al. The sequence of human serum
albumincDNA and its expressionin E. coli. NucleicAcidsRes 19~1 :22:
6103-14.
57. Sekiguchi K, Fukuda M, Hakamori 51. Domain structure of hamster
plasma fibroneetin. J Bioi Chem I9~ I;256:6452-62.
5~. Banyai L. Varadi A, Patthy L. Common evolutionary origin of the
fibrin-binding structures of fibroneetin and tissue-type plasminogen
activator. FEBS Lett 19~3:163:3741.
59. Petersen TE. Thogerxen He. Skorstengaard K, et al. Partial primary
structure of bovine plasma fibronectin: three types of internal homol-
ogy. Proe Natl Acad Sci USA I9iO:80: 137-41.
60. Miillertz S. A plasminogen activator in spontaneously active human
blood. Proc Soc Exp Med 1953:82:291-5.
61. Kagitani H, Tagawa M, Hatanaka K, et al. Expression in E. Coli of
finger-domain lacking tissue-type plasminogen activator with high fi-
brin affinity. FEBS Lett 1985:1~9:145-9.
62. van Zonncvcld AJ, Veerrnan H, Pannekoek H. Autonomous functions
of structural domains on human tissue-type plasminogen activator.
Proc Natl Acad Sci USA 19~6:83:4670-4.
63. Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of One-
chain and two-chain human extrinsic (tissue-type) plasminogen acti-
vator. J Bioi Chern 1982;257:2920-5.
64. Hoylaerts M. Rijken DC, Lijncn HR. Collen D. Kinetics of the ac-
tivation of plasminogen by human tissue plasminogen activator. J Bioi
Chern 1982;257:2912-9.
65. Ranby M. Bergsdorf N, Pohl G, et al. Isolation of two variants of
native one-chain tissue plasminogen activator. FEBS Lett 19~2:146:
2~9 ~lJ2.
66. Green GDJ. Poly-L-Iysines as modifiers of one- and two-chain tissue-
type plasminogen activator activity. Thromb Res 1986;44:849-57.
67. Bernik M. Kwaan HC. Plasminogen activator therapy in culture from
human tissue: an immunological and histochemical study. J Clin Invest
1969;48:1740-4.
68. Vetterlein D, Bell TE, Young PL, et al. Immunological quantitation
and imrnunoadsorption of urokinase-like plasminogen activators se-
creted by human cells. J Bioi Chern 1980:255:3665-72.
69. Subcommittee on Fibrinolysis of the ICTH. Report of the meeting of
the subcommittee on Fibrinolysis, San Diego, CA, USA, July 13,
1985. Thrornb Haernost 1985:54:893.
70. Gunzler WA. Steffens GJ, Otting F, et al. The primary structure of
high molecular mass urokinase from human urine. Hoppe-Seyler's Z
Physiol Chern 1982:363:1155-65.
71. Heyneker HL, Holmes WE, Vehar GA. Preparation of functional
human urokinase proteins. European Patent application no 83103629.8.
Publication no 009182A2. European Patent Office, Munich. West
Germany. 19~3.
72. Holmes WE. Heyneker HL. Vehar GA. Cloning and expression of
the gene for prourokinase in Escherichia coli. Biotechnology 1985:3:
923-9.
73. Lijnen HR, Zamarron C. Blaber M. et al. Activation of plasminogen
by pro-urokinase. I. Mechanism. J Bioi Chern 1986:261:1253-8.
74. Stump DC. Thienpont M, Collen D. Urokinase-related proteins in
human urine. Isolation and characterization of single chain urokinase
(pro-urokinase) and urokinase-inhibitor complex. J BioiChern 1986:261:
1267-73.
75. Wun TC, Schleuning WD, Reich E. Isolation and characterization of
urokinase from human plasma. J Bioi Chern 1982:257:3276-83.
76. Husain SS. Lipinski B. Gurewich V. Isolation of plasminogen acti-
vators useful as therapeutic diagnostic agents (single chain, high-fibrin
affinity urokinase). US patent no 4381346 (filed Nov 13, 1979. issued
Apr 26. 1(83).
77. Zamarron C, Lijnen HR, Van Hoef B, et al. Biological and throrn-
bolytic properties of proenzyme and active forms of human urokinase.
l. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro
of urokinase obtained from human urine or by recombinant DNA
technology. Thromb Haernost 1984:52:19-23.
7X. Gurewich V, Pannell R. Louie S, et al. Effective and fibrin-specific
clot lysis by a zymogen precursor form of urokinase (pro-urokinase).
A study in vitro and in two animal species. J Clin Invest 1984;73:
1731 -9.
79. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma
and of a mechanism for its selective fibrinolytic effect. Blood 19~6:67:
1215-23.
XO. Sottrup-Jensen L, Claeys H, Zajdel M, Petersen TE, Magnusson S.
In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC. edx.
Progressin Chemical Fibrinolysis and Thrombolysis. New York: Raven
Press, 1978:191-209.
81. Wiman B, Wallen P. The specific interaction between plasminogen
and fibrin. A physiological role of the lysine binding site in plasmin-
ogen. Thromb Res 1977:10:213-22.
X2. Nakayama Y, Shinohara M, Tani T. et al. The plasmin heavy chain
urokinase conjugate: a specific thrombolytic agent. Thromb Haernost
1986:56:369-70.
~3. Vitetta ES. Krolick KA. Miyama-Inaba M. Cushley W, Uhr JW.
lmmunotoxins: a new approach to cancer therapy. Science 19~.\ :219:
644-50.
X4. Tsukada Y, Hurwitz E, Kashi R. et al. Chemotherapy by intravenous
administration of conjugates of daunomycin with monoclonal and con-
ventional anti-rat o-fetoprotein antibodies. Proc Natl Acad Sci USA
I9~2:7lJ:7896-lJ.
~5. Torchilin VI', Maksimenko AV, lgnashenkova GV, et al. Fibrinolytic
action of enzyme preparation conjugated with specific antibodies. Bull
Exp BiolMed 19~4;4~:556-~.
86. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic
fibrin-likepeptide bond to a human fibrin but not to fibrinogen. Science
1983:222:1129-31.
87. Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed uro-
kinase: a specific fibrinolytic agent. Science 1985:229:765-7.
88. Haber E. In vivo diagnostic and therapeutic uses of monoclonal an-
tibodies in cardiology. Annu Rev Med 1986:37:249-61.
~lJ. Bode C. Runge MS. Matsueda GR. Haber E. Antifibrin-urokinase
complex. In: Eifert S. von Essen R, Hugenholtz PG, Uebis R, Ver-
straete M. eds. Facts and Hopes in Thrombolysis in Acute Myocardial
Infarction. Dietrich-Steinkoptf Verlag 1986:35-41.
90. van Zonneveld AJ, Veerman H. Pannekoek H. Autonomous functions
of structural domains on human tissue-type plasminogen activator.
Proc Natl Acad Sci USA 1986:83:4670-4.
91. MacDonald ME, vanZonneveld AJ, Pannekoek H. Functional analysis
of the human tissue-type plasminogen activator protein: the light chain.
Gene 1986;42:59-67.
92. Holvoet P, Lijnen HR, Collen D. Characterization of functional do-
mains on human tissue-type plasminogen activator with the use of
monoclonal antibodies. Eur J Biochem 1986:158:173-7.
93. van Zonneveld AJ, Chang TGT, Vanden Berg J, et al. Quantification
of tissue-type plasminogen activator (I-PA) mRNA in human endo-
thelial cell cultures by hybridization with a t-PA cDNA probe. Biochem
J 1986:235:385-lJO.
94. van Zonneveld AJ, Veerman H. Brakenhoff JPJ. et al. Mapping of
epitopes on human tissue-type plasminogen activator with recombinant
deletion mutant proteins. Thrornb Haernost 1987:57:82-6.
95. van Zonneveld AJ, Veerman H, Pannekoek H. On the interaction of
the finger and kringle-2 domain of tissue-type plasminogen activator
with fibrin. Inhibition of kringle-2 binding by l-aminocaproid acid.
J Bioi Chern 1986:267:14214-8.
96. Collen D. Molecularmechanism of action of newer thrombolyticagents.
J Am Coli Cardiol 1987:IO(suppl.):IIB-5B.
